Show simple item record

dc.contributor.authorLiew, D
dc.contributor.authorPatten, N
dc.contributor.authorTan, M
dc.contributor.authorKim, H
dc.date.accessioned2021-07-07T03:57:54Z
dc.date.available2021-07-07T03:57:54Z
dc.date.issued2017
dc.identifier.issn1098-3015en_US
dc.identifier.doi10.1016/j.jval.2017.08.260en_US
dc.identifier.urihttp://hdl.handle.net/10072/405766
dc.description.abstractObjectives: International five-year survival rates for metastatic kidney and renal pelvis cancer are estimated at between 12-20%, indicating significant unmet clinical need for effective therapies. Currently, everolimus is a subsidised treatment option in Australia for patients who have progressive disease following first-line treatment with a tyrosine kinase inhibitor. Nivolumab is the first immunotherapy agent explored in RCC (CheckMate-025) and this study sought to assess the cost utility of nivolumab versus everolimus. Methods: A 3-state (clinical progression free, clinical disease progression, dead) Markov model was developed with 2-week cycles. Individual patient data from the pivotal study directly informed the health state transition probabilities until a minimum follow-up of 14 months. Thereafter, survival curves were extrapolated to 10 years, followed by convergence of the curves at 20 years. Australian specific health state utilities, drug costs and disease management costs were drawn from published sources. A range of sensitivity analyses were undertaken to test the robustness of the results of the modelled economic evaluation. Results: Nivolumab added an average of 0.78 life years (LYs) and 0.65 quality adjusted life years (QALYs) per person at an additional cost of US$45,000 (discounted), resulting in ICERs of US$58,000/LY saved and US$69,000/QALY saved. The sensitivity analysis showed that the result was most sensitive to the time horizon and duration of treatment. However, the ICER was stable and generally stayed within +/-10% of the base case for most of the scenarios in tested in the sensitivity analyses.en_US
dc.languageenen_US
dc.publisherElsevier BVen_US
dc.relation.ispartofconferencenameISPOR 20th Annual European Congressen_US
dc.relation.ispartofconferencetitleValue in Healthen_US
dc.relation.ispartofdatefrom2017-11-04
dc.relation.ispartofdateto2017-11-08
dc.relation.ispartoflocationGlasgow, Scotlanden_US
dc.relation.ispartofpagefromA444en_US
dc.relation.ispartofpagetoA444en_US
dc.relation.ispartofissue9en_US
dc.relation.ispartofvolume20en_US
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciencesen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.fieldofresearchApplied Economicsen_US
dc.subject.fieldofresearchcode1115en_US
dc.subject.fieldofresearchcode1117en_US
dc.subject.fieldofresearchcode1402en_US
dc.titleCost Utility Analysis (CUA) of Nivolumab Compared To Everolimus for The Treatment of Metastatic Renal Cell Carcinoma (RCC) in Australiaen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationLiew, D; Patten, N; Tan, M; Kim, H, Cost Utility Analysis (CUA) of Nivolumab Compared To Everolimus for The Treatment of Metastatic Renal Cell Carcinoma (RCC) in Australia, Value in Health, 2017, 20 (9), pp. A444-A444en_US
dc.date.updated2021-07-06T00:37:24Z
gro.hasfulltextNo Full Text
gro.griffith.authorKim, Hansoo


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record